Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Tongjitang Chinese Medicines Reports Higher Q2

publication date: Aug 14, 2007
Stock Sells Off after Announcement Tongjitang Chinese Medicines Company (TCM), which makes and markets contemporary formulations of traditional Chinese medications, said its Q2 revenues were up 12% at 141 million RMB ($18.5 million). That pushed profits 5% higher to 56 million RMB ($7.3 million). The company said that, in comparison to a year ago, advertising costs were much higher in the current quarter, which kept a lid on earnings. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital